OncoMatch/Clinical Trials/NCT07135466
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
Is NCT07135466 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies non-drug interventions for b cell malignancies.
This is a phase I/II trial of T-cell expressing an anti-CD22 Chimeric-Antigen-Receptor (CAR) in patients with CD22 expressing B-cell malignancies. This trial is an open label, single-arm, for pediatric and adult patients with relapsed/refractory B-cell malignancies.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: CD22 expression (expression shown by flow cytometry on at least 70% of leukemic blasts / lymphoma cells)
CD22 expression shown by flow cytometry on at least 70% of leukemic blasts / lymphoma cells
Allowed: CD19 positive disease
including CD19-directed therapy (For CD19 positive disease)
Demographics
Prior therapy
Must have received: CD19-directed therapy
relapsed or refractory after receiving at least 2 lines of standard therapy including CD19-directed therapy (For CD19 positive disease)
Must have received: CAR-T cell therapy
Relapse following standard relapse protocol (2nd relapse), including CD19 CART
Must have received: induction chemotherapy
Primary refractory, i.e. failed to achieve morphologic remission after 2 lines of induction chemotherapy
Lab requirements
Cardiac function
LV ejection fraction >45% or shortening fraction >28%
Cardiac function: LV ejection fraction >45% or shortening fraction >28%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07135466 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received CD19-directed therapy and CAR-T cell therapy.
Does this trial require CD22?
Yes, CD22 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify